Active — Not RecruitingNot Applicable

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

Australia, Canada, Spain369 participantsStarted 2024-11-01

Plain-language summary

Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy. This study aims to clarify the role of fosfomycin as an adjunctive therapy for improving outcomes in patients with this serious infection. Two clinical trials suggested that adjunctive fosfomycin therapy might offer a clinical benefit in certain cases, but the results are inconclusive. We aim to analyse pooled data from these trials in order to identify subgroups of patients that might benefit most from this therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients included in the BACSARM and SAFO clinical trials. Exclusion Criteria: * For both trials: polymicrobial bacteraemia, severe clinical status with expected survival \< 24 hours, severe liver disease with Child-Pugh score class C, diagnosis of prosthetic infective endocarditis, allergy or known resistance to study drugs, pregnancy at the time of inclusion, inclusion in another clinical trial. * For the BACSARM trial: diagnosis of MRSA pneumonia, prior history of eosinophilic pneumonia, use of additional antibiotic therapy with microbiological activity against MRSA. * For the SAFO trial: prior history of myasthenia gravis, acute SARS-CoV2 infection.

What they're measuring

Treatment success at 8 weeks from the time of randomisation

Timeframe: 8 weeks from the time of randomisation

Trial details

NCT IDNCT06695832

SponsorHospital Universitari de Bellvitge

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-01-31

View on ClinicalTrials.gov More Staphylococcus Aureus Bacteremia trials